Literature DB >> 24812434

Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.

Yoichiro Hirakawa1, Hisatomi Arima1, Sophia Zoungas2, Toshiharu Ninomiya1, Mark Cooper3, Pavel Hamet4, Giuseppe Mancia5, Neil Poulter6, Stephen Harrap7, Mark Woodward1, John Chalmers8.   

Abstract

OBJECTIVE: There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial. RESEARCH DESIGN AND METHODS: ADVANCE was a factorial randomized controlled trial of intensive glucose control and blood pressure lowering in patients with type 2 diabetes. VVV in the intensive glucose treatment group was defined using the SD of five measurements of HbA1c and glucose taken 3-24 months after randomization. Outcomes were combined macro- and microvascular events and all-cause mortality occurring post 24 months. Sensitivity analyses were performed using other indices of variability and in the standard glucose treatment group.
RESULTS: Among 4,399 patients in the intensive group, an increase in VVV of HbA1c was associated with an increased risk of vascular events (P = 0.01) and with mortality (P < 0.001): highest versus lowest tenth hazard ratio (95% CI) 1.64 (1.05-2.55) and 3.31 (1.57-6.98), respectively, after multivariable adjustment. A clear association was also observed between VVV of fasting glucose and increased risk of vascular events (P < 0.001; 2.70 [1.65-4.42]). HbA1c variability was positively associated with the risk of macrovascular events (P = 0.02 for trend), whereas glucose variability was associated with both macro- and microvascular events (P = 0.005 and P < 0.001 for trend, respectively). Sensitivity analyses using other indices, and patients in the standard glucose treatment group, were broadly consistent with these results.
CONCLUSIONS: Consistency of glycemic control is important to reduce the risks of vascular events and death in type 2 diabetes.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24812434     DOI: 10.2337/dc14-0199

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  112 in total

1.  Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus.

Authors:  Florian C Bonke; Ewan Donnachie; Antonius Schneider; Michael Mehring
Journal:  Diabetologia       Date:  2015-10-30       Impact factor: 10.122

2.  Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes.

Authors:  Bao Sun; Fazhong He; Yongchao Gao; Jiecan Zhou; Lei Sun; Rong Liu; Heng Xu; Xiaoping Chen; Honghao Zhou; Zhaoqian Liu; Wei Zhang
Journal:  Endocrine       Date:  2019-03-13       Impact factor: 3.633

3.  A 3-year follow-up of the Silent Diabetes Study.

Authors:  Oliver Schnell; Rolf Doerr; Volker Lodwig; Joerg Weissmann; Tobias Lohmann
Journal:  Diabetologia       Date:  2014-09-17       Impact factor: 10.122

4.  Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478).

Authors:  Athena Philis-Tsimikas; Irene Stratton; Lone Nørgård Troelsen; Britta Anker Bak; Lawrence A Leiter
Journal:  J Diabetes Sci Technol       Date:  2019-04-11

5.  Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials.

Authors:  Jin J Zhou; Ruth Coleman; Rury R Holman; Peter Reaven
Journal:  Diabetologia       Date:  2020-09-21       Impact factor: 10.122

6.  Association between visit-to-visit variability of HbA1c and cognitive decline: a pooled analysis of two prospective population-based cohorts.

Authors:  Zhe-Bin Yu; Yao Zhu; Die Li; Meng-Yin Wu; Meng-Ling Tang; Jian-Bing Wang; Kun Chen
Journal:  Diabetologia       Date:  2019-09-04       Impact factor: 10.122

Review 7.  Utility of different glycemic control metrics for optimizing management of diabetes.

Authors:  Klaus-Dieter Kohnert; Peter Heinke; Lutz Vogt; Eckhard Salzsieder
Journal:  World J Diabetes       Date:  2015-02-15

Review 8.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

Review 9.  Glucose variability, HbA1c and microvascular complications.

Authors:  Jan Škrha; Jan Šoupal; Jan Škrha; Martin Prázný
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

10.  Translating What Works: A New Approach to Improve Diabetes Management.

Authors:  Lawrence S Phillips; Diana Barb; Chun Yong; Anne M Tomolo; Sandra L Jackson; Darin E Olson; Mary K Rhee; Ingrid M Duva; Qing He; Qi Long
Journal:  J Diabetes Sci Technol       Date:  2015-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.